Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus apatinib versus TACE plus placebo for primary liver cancer
ChiCTR1800019743Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in hepatocellular carcinoma (HCC) comparing TACE + placebo with TACE + apatinib (2 arms). Primary endpoint: progression-free survival. Started Dec 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800019743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019743.